FOCUS magazine showcases a selection of our original resources. You can use the educational content featured in FOCUS to identify and reduce barriers that prevent people from accessing the medicines they need.

Explore your prescribing further with EPiC Reflect CVD. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

Molnupiravir (Lagevrio) is an oral antiviral for treating patients with COVID-19 in the community.

Access criteria are the same as for nirmatrelvir/ritonavir (Paxlovid). Molnupiravir should only be used where nirmatrelvir/ritonavir is clinically inappropriate, as trial data suggest molnupiravir is much less effective. Read our article for details.

Explore your prescribing further with EPiC Reflect Annual Report. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

This workbook consists of introductory reading and five distinct modules that encourage you to reflect on your CVD risk assessment and management practices, risk communication, cultural safety, and your engagement with young adult Māori and Pacific patients.

Explore your prescribing further with EPiC Reflect Gout. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

Explore your prescribing further with EPiC Reflect Diabetes. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

Since 1 April 2022, the oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) has been listed on the Pharmaceutical Schedule for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria and to comprehensive drug interaction guidance.

This video demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.

Please note that this is the video version of the Legendary Conversations podcast Episode Four: Let's talk gout (part 2).

This podcast demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.

Please note that this is the podcast version of the video Let's talk gout.